American Academy of Dermatology Meeting
American Academy of Dermatology Meeting
Source/Disclosures
Source:

Tanghetti E et al. ePoster. Phase 3 study of tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris. Presented at AAD VMX; June 12-14, 2020; Virtual meeting.

Disclosures: Tanghetti has served as speaker for Novartis, Ortho Dermatologics, Sun, Lilly, Galderma, AbbVie, and Dermira; served as a consultant/clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure. See the presentation for a full list of authors’ disclosures.
June 15, 2020
1 min read
Save

Lower dose tazarotene lotion effective in acne lesion reduction

Source/Disclosures
Source:

Tanghetti E et al. ePoster. Phase 3 study of tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris. Presented at AAD VMX; June 12-14, 2020; Virtual meeting.

Disclosures: Tanghetti has served as speaker for Novartis, Ortho Dermatologics, Sun, Lilly, Galderma, AbbVie, and Dermira; served as a consultant/clinical studies for Hologic, Ortho Dermatologics, and Galderma; and is a stockholder for Accure. See the presentation for a full list of authors’ disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Once-daily use of tazarotene 0.045% reduced inflammatory and noninflammatory acne vulgaris lesions, according to a phase 3 study presented at the American Academy of Dermatology virtual meeting.

Tazarotene 0.045% lotion uses polymeric emulsion technology to distribute a lower dose of the drug compared to the widely used tazarotene products currently prescribed to acne vulgaris patients.

The phase 3, vehicle-controlled study randomized 813 patients into two treatment groups and evaluated progress from baseline to week 12.

Treatment success, defined as a reduction greater than or equal to a 2-grade reduction in Global Severity Score, was reported in 25.5% of patients in the treatment group after 12 weeks and 13% in the vehicle group (P < .001).

A mean percentage change in inflammatory lesions of 55.5% was recorded in the treatment group at week 12, compared to a change of 45.7% in the vehicle group. Noninflammatory lesions had a mean change of 51.4% in the tazarotene group at week 12, compared to 41.5% in the vehicle group.

“In this pivotal, phase 3 study, once-daily tazarotene 0.045% lotion was efficacious in patients with moderate-to-severe acne, providing significantly greater reductions in inflammatory and noninflammatory lesion counts and a greater proportion of participants achieving treatment success versus vehicle,” the study authors wrote.

Most treatment-related adverse events, including pain, dryness, erythema and exfoliation, were mild or moderate. Three patients in each group experienced a serious adverse event.